The analytes were detected in multiple reaction monitoring mode in MS. lactate and 2-HG Ntf3 in regulatory network and in metabolic symbiosis it could be assumed that mTOR inhibitors have additional effects besides their anti-proliferative effects in tumours with glycolytic phenotype, especially in case of mutation (e.g. acute myeloid leukemias, gliomas, chondrosarcomas). Based on our fresh results, we suggest focusing on mTOR activity depending on the metabolic and besides molecular genetic phenotype of tumours to increase the success of therapies. Electronic supplementary material The online version of this article (doi:10.1186/s13046-017-0544-y) contains supplementary material, which is available to authorized users. mutations are explained in 80% of gliomas, 20% of acute myeloid leukemias (AMLs) and in certain cholangiocarcinomas, thyroid cancers and chondrosarcomas [23, 25]. You will find no data available about the part of mTOR activity in 2-HG production in any homozygous or heterozygous IDH mutant cells. Considering the aberrant regulatory effect of mTOR in malignant cells the query has been tackled whether mTORC1 operates through controlling of oncometabolite build up in metabolic reprogramming. In the present work, a heterozygous mutant cell collection and its rapamycin sensitivity were analyzed in vitro and in vivo. Our fresh results proved the part of mTOR activity and the inhibitory effect of rapamycin both in lactate and in 2-HG oncometabolite productions of heterozygous mutant fibrosarcoma cells. Methods All materials were purchased from Sigma-Aldrich, except where it is indicated in the text. In vitro cell ethnicities and different treatments HT-1080 endogenous heterozygous mutant cell collection was utilized for both in vitro and in vivo experiments. HT-1080 (CCL121-ATCC); KMH2, DEV (human being Hodgkin lymphoma cells purchased from DSMZ), ZR-75.1 (CRL-1500-ATCC), U251 MG homozygous and genes were analysed after using program DNA Isolation kit for Cells and Cells (Roche), specific amplifications (AmpliTaqGold Expert Mix with the appropriate primers – exon4 forward: aaaactttgcttctaatttttctcttt; opposite: acatacaagttggaaatttctgg,; exon4 ahead: tctagactctactgccttcctc; opposite: gtcagtggatcccctctcca C AppliedBiosystems), purification (ExoSAP-IT C Affimetrix) and direct sequencing (25?cycles at 51?C, BigDye 3Terminator v3.1 Cycle Sequencing Phenacetin Kit in Genetic Analyser 3500 – Applied BioSystem). Metabolite analysis using liquid chromatography mass spectrometry Intracellular metabolites (lactate, citrate, malate, Phenacetin succinate, 2-HG) were extracted by a revised method based on Szoboszlai et al. . In brief, the cells were quenched in liquid nitrogen and extracted by mixture of MeOHCchloroformCH2O (9:1:1) and vortexed at 4?C. After centrifugation (15,000xg, 10?min, 4?C) the clear supernatants were kept at ?80?C. The samples were prepared for LC-MS from the founded derivatization based on the protocol of Jaitz et al. . For derivatization 3-nitrobenzyl-alcohol?+?trimethyl-chlorsilane were added to Phenacetin the dried samples, sonicated and incubated at 80?C for 45?min. The reaction was halted by 100?mM ammonium-hydrogencarbonate solution. After these processes the samples were diluted in acetonitrile-water remedy. Gradient elution was used with Phenacetin reversed-phase chromatography in Waters Acquity LC system. The detection was performed by Waters Micromass Quattro Micro triple quadrupole mass spectrometer (Waters Corporation, Milford MA, USA) using electrospray resource in the positive ion mode with solitary ion monitoring mode. Standards (L-lactic acid, L-malic acid, succinic acid, citric acid, D-2-hydroxyglutarate) and additional chemicals except for labelled substrates were purchased from Sigma-Aldrich for these measurements. The analytes were recognized in multiple reaction monitoring mode in MS. HT-1080 cells create only D-2-HG . Applying this method, we did not distinguish L- and D- 2-HG enantiomers and we use 2-HG, being a synonym for D-2-HG in the manuscript. For 13C-labelling, cells had been incubated with 10?mM U-13C-blood sugar or 4?mM U-13C- glutamine or 10?mM 2-13C-acetate (Cambridge Isotope Laboratories, Andover, MA, USA) in D5030 moderate for just one hour prior to the extraction. In vivo research with HT-1080 xenograft model Xenograft tumours had been set up in SCID mice by injecting 2??106 HT-1080 cells subcutaneously (s.c.) in to the sole area of 8C10-week-old (20C23?g) mice. Palpable tumours had been.